In a paper published online in advance in Nature this week, investigators at the Centre for Lymphoid Cancers and the Centre for Translational and Applied Genomics in Vancouver report their use of RNA-seq to show that a gene fusion involving the major histocompatibility complex class II transactivator CIITA occurs frequently in lymphoid cancers.